1CM
AXDX

1492 Capital Management’s Accelerate Diagnostics AXDX Stock Holding History

1492 Capital Management’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-44,975
Closed -$684K – 106
2022
Q3 		$684K Buy
+44,975
New +$744K 0.49% 66

Other funds holding AXDX

GAM
Griffin Asset Management New York $887M AUM 21.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

1492 Capital Management's AXDX Position: Q4 2022 in Review

1492 Capital Management sold out of Accelerate Diagnostics (AXDX) in Q4 2022, closing a stake of 44,975 shares — an estimated $684K sold.

1492 Capital Management first reported a position in AXDX in Q3 2022 and held it in 1 quarter. The position peaked at $684K in Q3 2022. 72 funds tracked by Wall St. Rank hold AXDX as of Q4 2022.

  • 1492 Capital Management reported no remaining Accelerate Diagnostics position as of Q4 2022 after selling out during the quarter.
  • 1492 Capital Management sold 44,975 Accelerate Diagnostics shares in Q4 2022, an estimated $684K.
  • 1492 Capital Management first reported a position in Accelerate Diagnostics in Q3 2022 and held it in 1 quarter.
  • 1492 Capital Management's Accelerate Diagnostics position peaked at $684K in Q3 2022.
  • 72 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2022.

Based on 1492 Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.